Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14140MR)

This product GTTS-WQ14140MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14140MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7229MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1182MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ9297MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ12707MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ12188MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ11100MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ9732MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ9165MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW